- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 6, 2024
Deals
MorphoSys’ long run ends with €2.7B Novartis takeout
Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma
BioCentury | Apr 19, 2023
Data Byte
ADCs overtake mAbs in AACR’s first-in-human abstracts
BioCentury’s analysis of 25 first-in-human studies presented at AACR 2023
BioCentury | Aug 5, 2022
Discovery & Translation
Daley lab’s iPSC-derived T cell differentiation method; plus Harbour’s CTLA-4 antibody and more
BioCentury’s roundup of translational news
BioCentury | Dec 9, 2017
Product Development
Multimodal meeting
ASH 2017 by the numbers: cell and gene therapies making inroads
BioCentury | Dec 8, 2017
Targets & Mechanisms
Epiphenomena at ASH
Epigenetics and cell therapies are preclinical hotspots at ASH 2017
Items per page:
1 - 8 of 8